ROSEN, LEADING INVESTOR COUNSEL, Encourages NRx Pharmaceuticals, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - NRXP, NRXPWNewsfile Corp • 03/09/22
NRXP; NRXPW Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies NRx Pharmaceuticals, Inc. Investors of Class Action and Lead Plaintiff Deadline: March 21, 2022Business Wire • 03/09/22
NRX INVESTOR NEWS: ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSE, Encourages NRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - NRXP, NRXPWNewsfile Corp • 03/07/22
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages NRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - NRXP; NRXPWPRNewsWire • 03/05/22
NRXP Investors Have Opportunity to Lead NRx Pharmaceuticals, Inc. Securities Fraud LawsuitPRNewsWire • 03/03/22
DEADLINE APPROACHING: NRx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NRXP; NRXPWPRNewsWire • 03/02/22
NRx Pharmaceuticals: Potential For First In Bipolar Depression Suicidal Ideation Treatment, Along As Covid-19 PlaySeeking Alpha • 02/23/22
NRx Pharmaceuticals Announces US National Institutes of Health Study of ZYESAMI® (aviptadil) in Critical COVID-19 is Cleared to Complete Full EnrollmentPRNewsWire • 02/15/22
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of NRx Pharmaceuticals, Inc. (NRXP) InvestorsPRNewsWire • 02/14/22
NOTICE: Investors in NRx Pharmaceuticals, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NRXP; NRXPWBusiness Wire • 02/12/22
NRx Reports Remarks by Israel Institute for Biological Research on the future of the BriLife™ Covid-19 Investigational VaccineGlobeNewsWire • 02/11/22
Shareholder Action Alert: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 02/04/22
Investor Action Reminder: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 02/03/22
NRx Pharmaceuticals Announces Closing of $25 Million Private Placement Priced at a Premium to Market Under Nasdaq RulesPRNewsWire • 02/03/22
Shareholder Action Notice: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 02/02/22
NRx Pharmaceuticals Announces $25 Million Private Placement Priced at a Premium to Market under Nasdaq RulesPRNewsWire • 01/31/22
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NRx Pharmaceuticals, Inc. (NRXP)Business Wire • 01/27/22
NRx Announces Publication of Initial Findings of BriLife® Vaccine-produced Antibodies Against Omicron VariantPRNewsWire • 01/27/22
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NRx Pharmaceuticals, Inc. (NRXP)Business Wire • 01/26/22
NRx Receives Initial Report of Patient Safety and Survival from Right to Try use of ZYESAMI® (aviptadil) during Omicron SurgePRNewsWire • 01/26/22
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of NRx Pharmaceuticals, Inc. (NRXP) InvestorsBusiness Wire • 01/24/22
Shareholder Alert: Robbins LLP Reminds Investors that NRx Pharmaceuticals, Inc. (NRXP) is Being Sued for Misleading ShareholdersBusiness Wire • 01/23/22